Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
To predict the need for additional local corticosteroids after receiving the 0.19 mg fluocinolone acetonide (FAc) implant in patients with macular edema secondary to non-infectious uveitis previously treated with local peribulbar corticosteroids. The number of corticosteroids required prior FAc, vis...
Main Authors: | Lucy Joanne Kessler, Grzegorz Łabuz, Gerd U. Auffarth, Ramin Khoramnia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/4/688 |
Similar Items
-
Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
by: Muaas Hikal, et al.
Published: (2021-09-01) -
Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant – A Case Report
by: Jorge Meira, et al.
Published: (2019-09-01) -
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
by: William Fusi-Rubiano, et al.
Published: (2018-09-01) -
Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report
by: Khushi Saigal, et al.
Published: (2024-01-01) -
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
by: Saedon H, et al.
Published: (2017-03-01)